Head-to-head evidence
infliximab vs infliximab-abda (Renflexis)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline
infliximab · Remicade
Marketed by Johnson & Johnson and partners
NCT04205643 · Phase 3 · completed
Randomized, quadruple-blinded, placebo-controlled, adequately powered (n=438 randomized into maintenance phase) Phase 3 trial with a hard clinical endpoint (clinical remission by modified Mayo score) that reached statistical significance in the favorable direction, satisfying the 'strong' definition.
Next expected readout: December 2026 · NCT06839820 (registry estimate)
infliximab-abda (Renflexis)
Marketed by Samsung Bioepis and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
infliximab · Remicade
Marketed by Johnson & Johnson and partners
NCT00094458 · Phase 3 · completed
This meets the 'strong' test: randomized, triple-blinded (participant/investigator/outcomes assessor), active-comparator (not merely placebo) design, adequately powered (n=508), a primary endpoint that is a hard clinical measure (corticosteroid-free clinical remission via CDAI), and the primary comparisons reached statistical significance in the favorable direction for the key comparisons (combo vs AZA and IFX vs AZA).
Next expected readout: October 2026 · NCT05043870 (registry estimate)
infliximab-abda (Renflexis)
Marketed by Samsung Bioepis and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: infliximab's landscape · infliximab-abda (Renflexis)'s landscape